Market Overview

Stifel Downgrades Regal Entertainment As Sale Process Has Ended


In a report published Friday, Stifel analyst Benjamin Mogil downgraded the rating on Regal Entertainment Group (NYSE: RGC) from Buy to Hold, but reiterated the $23.00 price target.

In the report, Stifel noted, “We are moving to a Hold rating following Regal's announcement that it had ended its sale process. Our valuation remains unchanged, and the rating is driven as valuation nears that level and the M&A uptick possibility abates. Operational fundamentals now fall back into focus and we suspect that the company's bias on the dividend front will be towards an increase in the regular rate, which is more rewarded by shareholders than special dividends.”

Regal Entertainment closed on Thursday at $21.09.

Latest Ratings for RGC

Jan 2018B. Riley FBRDowngradesBuyNeutral
Dec 2017MacquarieDowngradesOutperformNeutral
Dec 2017Moffett NathansonUpgradesSellNeutral

View More Analyst Ratings for RGC
View the Latest Analyst Ratings

Posted-In: Benjamin Mogil StifelAnalyst Color Downgrades Analyst Ratings


Related Articles (RGC)

View Comments and Join the Discussion!

Latest Ratings

COMMJP MorganInitiates Coverage On0.0
KEYWSunTrust Robinson HumphreyDowngrades0.0
ISRGCanaccord GenuityMaintains575.0
PBCTFig PartnersDowngrades0.0
CNSGabelli & Co.Downgrades0.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Wells Fargo Cautious On IBM, Notes Low Visibility And Transition Concerns

Depomed Surges 8% Following NUCYNTA Acquisition From Janssen Pharmaceuticals